Preemptive treatment helps in preventing skin toxicity with PanitumumabPatients receiving panitumumab for treating metastatic colorectal cancer can avoid some of the skin-associated toxicities with a preemptive and prophylactic skin regimen, as per data presented at the 2009 American Society of Clinical Oncology Gastrointestinal Cancers Symposium in San Francisco.

Edith Mitchell, M.D., a clinical professor in the Department of Medical Oncology at Jefferson Medical College of Thomas Jefferson University, presented data from the study that was the first prospective study for comparing preemptive and reactive skin treatment for skin toxicities related to panitumumab.

The study was co-led by Dr. Mitchell and Mario Lacouture, M.D., an assistant professor of Dermatology at Northwestern University‘s Feinberg School of Medicine in Chicago.